Quarterly Report · 10-Q
TELA Bio, Inc.
TELANASDAQEQUITYCurrent
Quarterly Report
Company context
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by Stonepine Capital Management, LLC regarding TELA Bio, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding TELA Bio, Inc.Nov 13, 2026
- SCHEDULE 13G/A - filed by NORTH RUN CAPITAL, LP regarding TELA Bio, Inc.Nov 13, 2026
- S-3 filingNov 10, 2026
- 10-Q filingNov 10, 2026
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗